Riastap (fibrinogen)
Antifibrinolytics Intravenous Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Commercially available fibrinogen (human) is a sterile lyophilized concentrate of highly purified fibrinogen (blood coagulation factor I) prepared from pooled human plasma from suitable donors.
Fibrinogen (human) is a highly purified preparation of fibrinogen derived from pooled human plasma. Fibrinogen is a substrate of thrombin, factor VIII, and plasmin. During the coagulation process, thrombin cleaves fibrinogen, catalyzing a series of steps that ultimately result in formation of a stable fibrin clot.
Plasma used in the preparation of fibrinogen are screened for human viruses (e.g., hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)). Additional viral purification steps are employed to further reduce the risk of pathogen transmission.
Generic name: fibrinogen
Drug class: Antifibrinolytics
Therapeutic class: Hematological Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Riastap
Indications
The following indications are listed for Riastap:
- Afibrinogenemia
- Hypofibrinogenemia
Also known as: Factor I Deficiency, Fibrinogen Deficiency.
Dosing
Dosage is individualized based on the extent of bleeding, laboratory test results, and the clinical condition of the patient.
Dosage is expressed in mg of fibrinogen and is based on weight.
Data from a pharmacokinetic study in 14 patients (age range: 8-61 years) indicate that administration of 70 mg/kg of fibrinogen (human) increases plasma concentration of fibrinogen by approximately 120 mg/dL.
The recommended dose for patients when the baseline fibrinogen level is known is determined using the following formula:
The recommended dose for patients when the baseline fibrinogen level is not known is 70 mg/kg.
Fibrinogen (human) is administered by slow IV injection using a dedicated line.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
History of serious immediate hypersensitivity reactions (e.g., anaphylaxis) to fibrinogen (human) or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
- Thromboembolic disorder
- Thrombotic disorder
There are no moderate contraindications for this drug.
Adverse reactions
Fever, headache.
Less Frequent
- Thrombotic disorder
Rare or Very Rare
- Anaphylaxis
- Hypersensitivity drug reaction
Less Frequent
- Back pain
- Fever
- Headache disorder
- Pain in extremities
Rare or Very Rare
- Chest pain
- Cough
- Dyspnea
- Nausea
- Skin rash
- Vomiting
Precautions
No enhanced messaging available.
Evaluated in a limited number of children younger than 16 years of age. Individuals younger than 16 years of age clear fibrinogen faster than adults.
Category C. (See Users Guide)
Not studied in nursing women with congenital fibrinogen deficiency.
Experience in those 65 years of age or older insufficient to determine whether geriatric adults respond differently than younger adults.
ICD codes
| Code | Type | Description |
|---|---|---|
| Afibrinogenemia | ||
| D68.2 | ICD10CM | Hereditary deficiency of other clotting factors |
| Hypofibrinogenemia | ||
| D68.2 | ICD10CM | Hereditary deficiency of other clotting factors |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.